Study of Benralizumab in People With Skin Side Effects Caused by Cancer Therapies

Inclusion Criteria:

* Patients must have pathologically or cytologically confirmed solid or hematologic cancers.

OR

* Patient is receiving alpelisib for PIK3CA-Related Overgrowth Spectrum disorder.
* Female and male aged 18 to 85 years, inclusively, at the time of Week 0/Day 1 of treatment.
* Patients must have a therapy-related CTCAE grade 2/3 (See Appendix A)cutaneous adverse event defined as any cutaneous reaction listed below and blood eosinophil counts of at least .3 K/mcl.

  * Rash maculo-papular
  * Bullous dermatitis
  * Pruritus
  * Urticaria
  * Eczema
* Patients must plan to continue on culprit drugs (cancer patients).
* Patients planning to receive alpelisib indicated for PIK3CA-Related Overgrowth

Spectrum disorder OR patients receiving immunotherapy and/or targeted therapy, including but not limited to the following agents, will be eligible for inclusion:

* Immunotherapies: ipilimumab, nivolumab, pembrolizumab, avelumab, durvalumab, atezolizumab tremelimumab.
* Targeted therapies: trastuzumab, pertuzumab, alpelisib, osimertinib, everolimus, temsirolimus, sorafenib, regorafenib.

  * Patients using topicals/orals for indication of skin rash/pruritus for at least 7 days should continue using these drugs for the study duration
  * Adequate bone marrow, liver and renal function:
* Total bilirubin ≤ 1.5 x the upper limit of normal (ULN)
* Alanine aminotransferase (ALT) and aspartate amino-transferase (AST) ≤ 2.5 x ULN (≤ 5 x ULN for subjects with liver involvement of their cancer)
* Serum creatinine ≤ 1.8 xULN or calculated creatinine clearance \>45 ml/min
* Platelet count \> 50 K/mcL , hemoglobin (Hb) \> 8 g/dL, absolute neutrophil count (ANC) \>1.0 K/mcL. Blood transfusion to meet the inclusion criteria will not be allowed.

  * ECOG performance status 0-1 (see Appendix C).
  * Subjects must be able to understand and be willing to sign the written informed consent form. A signed informed consent form must be appropriately obtained prior to the conduct of any trial-specific procedure.
  * Female patients are authorized to participate if they meet the following criteria:
* Women of child bearing potential must meet both of the following conditions:
* Have a negative serum pregnancy test prior to enrollment and within 14 days prior to administration of the investigational product (IP).
* Patient must use an effective form of birth control (confirmed by the Investigator) throughout the study duration and within 16 weeks after last dose of IP.
* Female subjects who cannot bear children as evidenced by one or more of the following:
* Bilateral Oophorectomy
* Bilateral Salpingectomy
* Bilateral Salpingectomy-Oophorectomy
* Hysterectomy
* Menopause (no menses ≥ 1 year prior to treatment)
* Surgical Sterilization (i.e., tubal ligation or blockage) Note: If criteria not met, patient should be regarded as having child bearing potential

  * Subject must be able to receive a subcutaneous injection.
  * New/worsening ercAE within 90 days prior to study enrollment. Note: This assessment will be performed by the treating investigator.

Exclusion Criteria:

* Concurrent use of another investigational drug or device for the ercAE (i.e., outside of study treatment) during, or within 4 weeks of treatment.
* Patients receiving prednisone ≥ 20mg a day.
* Known use of anti-IL-5 agents or biologics for the treatment of asthma which are known to decrease blood eosinophil levels.
* Patients cannot use new topicals or medications for indication of pruritus or skin rash
* Known history of anaphylaxis to biologic therapy.
* A helminthic parasitic infection diagnosed within 24 weeks prior to the first treatment, that had not been treated with, or has failed to respond to, standard of care therapy.
* Known history of human immunodeficiency virus (HIV) infection or current chronic or active hepatitis B or C infection requiring treatment with antiviral therapy.
* Active infection that would impair the ability of the patient to receive study treatment.
* Women who are pregnant or breast-feeding.
* Any condition which, in the investigator's opinion, makes the subject unsuitable for trial participation.
* Receipt of live attenuated vaccines 30 days prior to the date of randomization

  ° Receipt of inactive/killed vaccinations (e.g., inactive influenza) is allowed provided they were not administered within 1 week before/after any investigational product administration.
* Known history of allergy or reaction to the investigational product formulation